MX363191B - Derivado de pirazol. - Google Patents

Derivado de pirazol.

Info

Publication number
MX363191B
MX363191B MX2015013333A MX2015013333A MX363191B MX 363191 B MX363191 B MX 363191B MX 2015013333 A MX2015013333 A MX 2015013333A MX 2015013333 A MX2015013333 A MX 2015013333A MX 363191 B MX363191 B MX 363191B
Authority
MX
Mexico
Prior art keywords
disease
formula
xanthine oxidase
drug
compound
Prior art date
Application number
MX2015013333A
Other languages
English (en)
Other versions
MX2015013333A (es
Inventor
Takahashi Hiroyuki
Takahashi Yoshimasa
Kawana Asahi
Kanazawa Chikashi
Tera Masayuki
Imazeki Mariko
Tanokura Akira
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MX2015013333A publication Critical patent/MX2015013333A/es
Publication of MX363191B publication Critical patent/MX363191B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan un compuesto expresado por la Fórmula (I) o una sal permitida farmacológicamente del mismo, así como un fármaco o composición de fármaco que contiene este compuesto como un ingrediente activo, que tiene un efecto inhibidor de xantina oxidasa, que es muy útil para tratar o prevenir enfermedades que son aportadas por la xantina oxidasa, tal como gota, hiperuricemia, síndrome de lisis de tumor, piedras en el tracto urinario, hipertensión, dislipidemia, diabetes, enfermedad cardiovascular tal como falla cardiaca y esclerosis arterial, enfermedad renal tal como opacidad casi diabética y similares, enfermedad respiratoria tal como enfermedad pulmonar obstructiva crónica y similares, enfermedades autoinmunes tales como enfermedad de intestino inflamatorio, y similares. [En la Fórmula, A, X, Y, Z, R, y R1 tienen el significado establecido en la reivindicación 1.] (ver Fórmula).
MX2015013333A 2013-03-29 2014-03-28 Derivado de pirazol. MX363191B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013072788 2013-03-29
PCT/JP2014/059912 WO2014157740A1 (ja) 2013-03-29 2014-03-28 ピラゾール誘導体

Publications (2)

Publication Number Publication Date
MX2015013333A MX2015013333A (es) 2016-01-25
MX363191B true MX363191B (es) 2019-03-14

Family

ID=51624694

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013333A MX363191B (es) 2013-03-29 2014-03-28 Derivado de pirazol.

Country Status (31)

Country Link
US (1) US9617240B2 (es)
EP (1) EP2980085B1 (es)
JP (1) JP6091603B2 (es)
KR (1) KR20150138212A (es)
CN (1) CN105189476B (es)
AU (1) AU2014244855B2 (es)
BR (1) BR112015024462A2 (es)
CA (1) CA2904142A1 (es)
CY (1) CY1120672T1 (es)
DK (1) DK2980085T3 (es)
ES (1) ES2666918T3 (es)
HK (1) HK1219099A1 (es)
HR (1) HRP20180644T1 (es)
HU (1) HUE037813T2 (es)
IL (1) IL241772B (es)
LT (1) LT2980085T (es)
ME (1) ME03055B (es)
MX (1) MX363191B (es)
MY (1) MY176149A (es)
NO (1) NO2980085T3 (es)
NZ (1) NZ712680A (es)
PH (1) PH12015502264A1 (es)
PL (1) PL2980085T3 (es)
PT (1) PT2980085T (es)
RS (1) RS57154B1 (es)
RU (1) RU2632884C2 (es)
SA (1) SA515361238B1 (es)
SG (1) SG11201507939XA (es)
SI (1) SI2980085T1 (es)
WO (1) WO2014157740A1 (es)
ZA (1) ZA201507146B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180095594A (ko) 2015-12-18 2018-08-27 노파르티스 아게 인단 유도체 및 가용성 구아닐레이트 시클라제 활성화제로서의 그의 용도
JP6732004B2 (ja) 2016-02-19 2020-07-29 国立大学法人鳥取大学 認知症治療薬または予防薬

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346094A (en) * 1980-09-22 1982-08-24 Eli Lilly And Company 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels
US4495195A (en) 1982-11-01 1985-01-22 Eli Lilly And Company Xanthine oxidase inhibiting 3(5)-phenyl-substituted-5(3)-pyrazole-carboxylic acid derivatives, compositions, and methods of use
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
JPH10310578A (ja) 1996-11-13 1998-11-24 Yoshitomi Pharmaceut Ind Ltd ３−フェニルピラゾール化合物
BR9910578A (pt) * 1998-04-28 2001-01-09 Novartis Ag Derivados de piridina substituìda por n-heteroarila e seu uso como herbicidas
WO1999065885A1 (en) * 1998-06-19 1999-12-23 Teijin Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
MXPA06012595A (es) * 2004-04-29 2007-05-09 Abbott Lab Analogos de amino-tetrazoles y metodos de uso.
JP2007043457A (ja) 2005-08-03 2007-02-15 Masamichi Mochizuki 携帯電話
JP4849594B2 (ja) 2005-09-30 2012-01-11 フマキラー株式会社 送風式薬剤放散装置
EP1932833B1 (en) 2005-10-07 2012-08-01 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
KR20080051157A (ko) * 2005-10-07 2008-06-10 아스텔라스세이야쿠 가부시키가이샤 트리아릴카르복시산 유도체
US8067446B2 (en) 2006-02-24 2011-11-29 Astellas Pharma Inc. Methods for treating an ulcer of the small intestine and stomach
BRPI0710110A2 (pt) * 2006-03-31 2011-08-02 Novartis Ag compostos orgánicos
JP5132132B2 (ja) 2006-11-17 2013-01-30 ヤマハ発動機株式会社 船舶用操舵装置及び船舶
JP2008126770A (ja) 2006-11-17 2008-06-05 Big Tool Co Ltd 自動車用窓ガラスの取り外し方法
WO2008126772A1 (ja) 2007-04-05 2008-10-23 Astellas Pharma Inc. 高血圧治療剤
WO2008126770A1 (ja) 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
WO2010044403A1 (ja) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 ５員環ヘテロアリール誘導体及びその医薬用途
EP2456311A4 (en) * 2009-07-24 2013-01-23 Concert Pharmaceuticals Inc SUBSTITUTED IMIDASOTRIAZINES
EP2789614B1 (en) * 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
JP4939578B2 (ja) 2009-08-19 2012-05-30 株式会社沖データ 現像剤搬送装置、現像剤収容器、及び画像形成装置
TWI423962B (zh) 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物

Also Published As

Publication number Publication date
PL2980085T3 (pl) 2018-10-31
PT2980085T (pt) 2018-04-09
EP2980085B1 (en) 2018-03-14
WO2014157740A1 (ja) 2014-10-02
EP2980085A1 (en) 2016-02-03
RS57154B1 (sr) 2018-07-31
JPWO2014157740A1 (ja) 2017-02-16
DK2980085T3 (en) 2018-05-22
US20160039784A1 (en) 2016-02-11
ZA201507146B (en) 2016-10-26
LT2980085T (lt) 2018-05-10
NZ712680A (en) 2020-02-28
MX2015013333A (es) 2016-01-25
IL241772B (en) 2018-02-28
PH12015502264B1 (en) 2016-02-01
HUE037813T2 (hu) 2018-09-28
CY1120672T1 (el) 2019-12-11
AU2014244855A1 (en) 2015-09-24
US9617240B2 (en) 2017-04-11
CN105189476B (zh) 2017-07-07
BR112015024462A2 (pt) 2017-07-18
RU2632884C2 (ru) 2017-10-11
HRP20180644T1 (hr) 2018-06-01
NO2980085T3 (es) 2018-08-11
CN105189476A (zh) 2015-12-23
HK1219099A1 (zh) 2017-03-24
ES2666918T3 (es) 2018-05-08
ME03055B (me) 2018-10-20
SA515361238B1 (ar) 2018-01-11
SG11201507939XA (en) 2015-11-27
MY176149A (en) 2020-07-24
AU2014244855B2 (en) 2018-04-05
SI2980085T1 (en) 2018-08-31
JP6091603B2 (ja) 2017-03-08
KR20150138212A (ko) 2015-12-09
EP2980085A4 (en) 2016-04-13
CA2904142A1 (en) 2014-10-02
PH12015502264A1 (en) 2016-02-01

Similar Documents

Publication Publication Date Title
PH12018500261B1 (en) Azole benzene derivative
BR112012033715A2 (pt) inibidores de quinase de regulação de sinal de apoptose.
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
ME03016B (me) Derivat piridina
HRP20151399T1 (hr) Kinazni inhibitor koji regulira signalni put apoptoze
WO2010084169A3 (en) Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
WO2007087204A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
MX2015008090A (es) Compuestos de piridina-2-carboxamida sustituida como inhibidores de cinasa reguladora de señal de apoptosis.
WO2014099633A3 (en) Inhibitors of the renal outer medullary potassium channel
JP2014012726A5 (es)
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
NZ605690A (en) Oxadiazole inhibitors of leukotriene production
BRPI1011804A2 (pt) composição farmacêutica com solubilidade melhorada
MX339829B (es) Metodo para estabilizar daño de articulacion en sujetos utilizando inhibidores de xantina oxidoreductasa.
WO2013014204A3 (en) 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
WO2012094462A3 (en) Heterocyclic compounds for the inhibition of pask
PH12015502264A1 (en) Pyrazole derivative
WO2011028737A3 (en) Bisphosphonate compositions and methods for treating heart failure
GB201116017D0 (en) Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
EA201270653A1 (ru) Антагонист dpи его применение
BR112014018226A8 (pt) Derivados de pirimidooxazocina como inibidores de mtor
NZ624714A (en) Methods for treating gout in patient subpopulations
JP2014532758A5 (es)
WO2011156554A8 (en) Cyclohexyl-azetidinyl antagonists of ccr2